EUR 300.09 For Business Accounts Only

Generics in the United States

Summary

Generics in the United States industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2014-18, and forecast to 2023). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Highlights

- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
- The US generics market had total revenues of $104.8bn in 2018, representing a compound annual growth rate (CAGR) of 5.4% between 2014 and 2018.
- Market consumption volume increased with a CAGR of 0.7% between 2014 and 2018, to reach 90.4% of total pharma volume.
- The Drug Competition Action Plan (DCAP) announced in May 2017 that it wants to encourage generic drug manufacture and not allow patients to be priced out of drugs that they need.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in the United States
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in the United States
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the United States generics market with five year forecasts by both value and volume

Reasons to buy

- What was the size of the United States generics market by value in 2018?
- What will be the size of the United States generics market in 2023?
- What factors are affecting the strength of competition in the United States generics market?
- How has the market performed over the last five years?
- How large is the United States’s generics market in relation to its regional counterparts?